n Cardiovascular Journal of South Africa - Major trial shows cardiovascular benefits using new drug combination with perindopril : drug trends in cardiology




Extracted from text ... A panel of international experts has halted the blood pressure arm of the Anglo- Scandinavian Cardiac Outcomes Trial (ASCOT)1 because of substantial benefits in favour of the amlodipine/perindoprilbased treatment strategy. ASCOT is a major multinational trial, involving over 19 000 hypertensive patients from Scandanavia, Ireland and the United Kingdom, that compares the effectiveness of two different treatment strategies in reducing cardiovascular events, including heart attack and stroke. The combination therapy using the calcium channel blocker amlodipine (Norvasc), and the angiotensin converting enzyme inhibitor perindopril (Coversyl), was found to offer significant advantages over the beta-blocker atenolol, and the thiazide diuretic bendroflumethiazide, ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error